| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 1.3K | 10.8% | 11.2% |
| Total Income | 1.3K | 2.3% | 10.8% |
| Expenditure | 1.2K | 12.0% | 10.0% |
| PBT | 146.60 | 40.3% | 42.0% |
| Net Profit | 129.28 | 37.9% | 51.0% |
| OPM | 17.63% | 1.84pp | 1.63pp |
| NPM | 9.71% | 6.28pp | 2.59pp |
| EPS | 13.77 | 37.2% | 54.4% |
Strides FY26 EBITDA at ₹9,253m, PAT up 50% YoY
18 May 2026 · 18 May, 2:29 pm
Summary
Strides Pharma Science Ltd. announced a strong financial performance for the full year FY26, with EBITDA reaching ₹9,253m, up 15.3% Year-on-Year, and Operational PAT surging by 50.3% to ₹5,181m. The company's Ex-US markets were a primary growth driver, achieving 21% YoY revenue growth. This performance led to an expanded EBITDA margin of 19.0% for FY26, an improvement of 140bps YoY. Management attributed the success to a continued focus on profitability and a calibrated strategy in Ex-US markets, while reiterating commitment to long-term sustainable and profitable growth.
Key Highlights
- 1
Strides Pharma Science Ltd. reported a full-year FY26 EBITDA of ₹9,253m, marking a strong 15.3% Year-on-Year growth.
- 2
Operational PAT for FY26 surged by 50.3% Year-on-Year to ₹5,181m, reflecting significant operating leverage.
- 3
Ex-US Market Revenue delivered robust growth of 21% Year-on-Year, reaching ₹22,404m ($254m) in FY26.
- 4
The company's EBITDA Margin expanded by 140bps Year-on-Year to 19.0% for FY26, driven by disciplined execution.
- 5
Net Debt to EBITDA improved to 1.55x in FY26 from 1.9x in FY25, indicating enhanced financial efficiency.
- 6
The Board recommended a dividend of ₹5 per share for the financial year FY26.
- 7
Q4FY26 revenue increased by 11.2% Year-on-Year to ₹13,235m.
Management Comments
Badree Komandur
Strides continued to deliver strong performance across profitability, efficiency, and growth metrics during FY26. This was primarily driven by the Ex‑US markets, which recorded a growth of 21% YoY. Our continued focus on profitability drove gross margin expansion of 310bps YoY and EBITDA margin improvement of 140bps YoY to 19%. Operational PAT and EPS grew by 50% YoY, reflecting strong operating leverage. Our calibrated strategy in Ex‑US markets is delivering results, with these markets outpacing overall company growth. The US business remained stable during the year, though impacted by a weaker flu season in the second half. Despite ongoing geopolitical uncertainties and a challenging external environment, we are committed to delivering to long term sustainable and profitable growth.
Informational and educational content only. Not investment advice.